Basel Medical Group (BMGL) closes US$6.5M Bethesda Medical acquisition in Singapore

Rhea-AI Filing Summary

Basel Medical Group Ltd reports that its subsidiary Basel Medical Group Pte. Ltd. completed the acquisition of all issued ordinary shares of Bethesda Medical Pte. Ltd., a Singapore-incorporated company. The deal was signed on April 11, 2025 and closed on April 30, 2025, making Bethesda Medical a wholly owned indirect subsidiary of Basel Medical Group Ltd.

At completion, the subsidiary paid the seller, Silkroute Biomed Healthcare Pte. Ltd., US$6.5 million. An additional deferred consideration of US$1.5 million was later agreed to be waived, so the total consideration for the acquisition was fully settled at US$6.5 million. This filing mainly updates investors on the final purchase price and ownership structure following the transaction.

Insights

Cross-border healthcare M&A analyst

Basel Medical finalizes a US$6.5M Singapore clinic acquisition on improved terms.

The company’s subsidiary completed the purchase of all ordinary shares of Bethesda Medical Pte. Ltd. in Singapore, with the transaction closing on April 30, 2025. Bethesda Medical is now a wholly owned indirect subsidiary of Basel Medical Group Ltd, which expands the group’s operational footprint in Singapore’s healthcare market.

Initially, the structure included a completion payment of US$6.5 million plus deferred consideration of US$1.5 million. The parties later agreed to waive that deferred component, leaving total consideration at US$6.5 million. This adjustment reduces the cash outlay relative to earlier expectations and clarifies the final economics of the acquisition, though the broader impact depends on Bethesda Medical’s contribution, which is not detailed here.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-42527

Basel Medical Group Ltd

6 Napier Road,

Unit #02-10/11 Gleneagles Medical Centre

Singapore 258499

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Explanatory Note

On April 11, 2025, Basel Medical Group Pte. Ltd. (“BMGPL”), a subsidiary of Basel Medical Group Ltd (Nasdaq: BMGL), entered into a sale and purchase agreement (the “Sale and Purchase Agreement”) with Silkroute Biomed Healthcare Pte. Ltd. (the “Seller”) for the acquisition of all of the ordinary shares in the issued and paid-up share capital (the “Sale Shares”) of Bethesda Medical Pte. Ltd., a company incorporated in Singapore (“Bethesda Medical”). The acquisition of Bethesda Medical pursuant to the Sale and Purchase Agreement was completed on April 30, 2025. Following such completion, Bethesda Medical became a wholly owned indirect subsidiary of Basel Medical Group Ltd. Upon completion, BMGPL paid the Seller a sum of US$6.5 million for such acquisition, and subsequently BMGPL and the Seller further agreed that the remaining deferred consideration of US$1.5 million shall be waived. Following such agreement, the total consideration of US$6.5 million for the acquisition of Bethesda Medical has been fully satisfied by BMGPL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Basel Medical Group Ltd
	By:	/s/ Darren Yen Feng Chhoa
	Name:	Dr. Darren Yen Feng Chhoa
	Title:	Chief Executive Officer
Date: January 21, 2026

FAQ

What acquisition did Basel Medical Group Ltd (BMGL) complete?

Basel Medical Group Ltd, through its subsidiary Basel Medical Group Pte. Ltd., completed the acquisition of all ordinary shares of Bethesda Medical Pte. Ltd., a company incorporated in Singapore.

How much did Basel Medical Group ultimately pay for Bethesda Medical?

The subsidiary paid the seller US$6.5 million at completion, and a previously agreed deferred consideration of US$1.5 million was later waived, so the total consideration was US$6.5 million.

When was the Bethesda Medical acquisition by BMGL signed and completed?

The sale and purchase agreement was entered into on April 11, 2025, and the acquisition was completed on April 30, 2025.

What is Bethesda Medical’s relationship to Basel Medical Group after the transaction?

Following completion of the transaction, Bethesda Medical Pte. Ltd. became a wholly owned indirect subsidiary of Basel Medical Group Ltd.

Who sold Bethesda Medical to Basel Medical Group’s subsidiary?

The seller was Silkroute Biomed Healthcare Pte. Ltd., which transferred all of the ordinary shares in the issued and paid-up share capital of Bethesda Medical to Basel Medical Group Pte. Ltd.

What is the purpose of this Basel Medical Group (BMGL) Form 6-K?

The Form 6-K provides an explanatory note updating investors that the Bethesda Medical acquisition has closed and that the final consideration is US$6.5 million after waiving the deferred portion.